A recent article in Blood Advances by Short et al entitled “Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia,” had very interesting conclusions that we are eager to interpret alongside our own published data on a similar topic. Herein, we will summarize the fundamental problem with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), summarize the data by Short et al1 and our own institutional data, and postulate a call to action to help motivate groups to collaborate on the issue of TP53-mutant MDS and AML.